Literature DB >> 21455857

Thrombosis and sickle cell disease.

Lucia De Franceschi1, Maria Domenica Cappellini, Oliviero Olivieri.   

Abstract

Sickle cell disease (SCD) is characterized by the presence of sickle hemoglobin, which has the unique property of polymerizing when deoxygenated. The pathophysiology of acute and chronic clinical manifestations of SCD have shown the central role of dense, dehydrated red cells in acute and chronic clinical manifestations of this pathology. Recent studies have indicated that SCD is characterized by a hypercoagulable state that contributes to the vaso-occlusive events in microcirculation, leading to acute and chronic sickle cell-related organ damage. This review discusses, in the context of SCD, (1) abnormalities in the coagulation system, (2) perturbation of platelet activation and aggregation, (3) vascular endothelial dysfunction, (4) the contribution of cell inflammatory responses, and (5) the connection with nitric oxide metabolism. We also review the available studies on the therapeutic approaches in clinical management of hypercoagulability in SCD. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21455857     DOI: 10.1055/s-0031-1273087

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  55 in total

Review 1.  Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.

Authors:  Dachuan Zhang; Chunliang Xu; Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

2.  Dietary ω-3 fatty acids protect against vasculopathy in a transgenic mouse model of sickle cell disease.

Authors:  Brian T Kalish; Alessandro Matte; Immacolata Andolfo; Achille Iolascon; Olga Weinberg; Alessandra Ghigo; James Cimino; Angela Siciliano; Emilio Hirsch; Enrica Federti; Mark Puder; Carlo Brugnara; Lucia De Franceschi
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

3.  Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1.

Authors:  Alessandro Matte; Antonio Recchiuti; Enrica Federti; Bérengère Koehl; Thomas Mintz; Wassim El Nemer; Pierre-Louis Tharaux; Valentine Brousse; Immacolata Andolfo; Alessia Lamolinara; Olga Weinberg; Angela Siciliano; Paul C Norris; Ian R Riley; Achille Iolascon; Charles N Serhan; Carlo Brugnara; Lucia De Franceschi
Journal:  Blood       Date:  2018-11-07       Impact factor: 22.113

Review 4.  Tissue factor and thrombin in sickle cell anemia.

Authors:  Pichika Chantrathammachart; Rafal Pawlinski
Journal:  Thromb Res       Date:  2012-03-06       Impact factor: 3.944

Review 5.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

6.  Efficient Quantitative Analysis of Carboxyalkylpyrrole Ethanolamine Phospholipids: Elevated Levels in Sickle Cell Disease Blood.

Authors:  Junhong Guo; Hua Wang; Borys Hrinczenko; Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2016-06-24       Impact factor: 3.739

7.  Paradoxical protection from atherosclerosis and thrombosis in a mouse model of sickle cell disease.

Authors:  Hui Wang; Wei Luo; Jintao Wang; Chiao Guo; Stephanie L Wolffe; Julia Wang; Eddy B Sun; Kori N Bradley; Andrew D Campbell; Daniel T Eitzman
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

Review 8.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 9.  Imaging of musculoskeletal manifestations in sickle cell disease patients.

Authors:  Vijaya Kosaraju; Alok Harwani; Sasan Partovi; Nicholas Bhojwani; Vasant Garg; Sabarish Ayyappan; Christos Kosmas; Mark Robbin
Journal:  Br J Radiol       Date:  2017-03-10       Impact factor: 3.039

Review 10.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.